Research & Development

Cannabinoid Purification and Scale-Up on Hipersep^® Pilot

For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.

PureO₃ Dissolved Ozone Sensor

The new pureO₃ Dissolved Ozone Sensor with Intelligent Sensor Management (ISM^®) technology provides robust, reliable measurement with increased stability in pure water applications.

Autobahn Therapeutics launches with $76m Series B financing to develop next generation therapies for CNS disorders

Financing co-led by ARCH Venture Partners and Cowen Healthcare Investments

MMS to support IGY Life Sciences in advancing Covid-19 antibody candidate

IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.

AbbVie, HBM, UU, and EMC to develop Covid-19 antibody therapeutic

AbbVie has joined forces with Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) to develop a novel antibody therapeutic for the prevention and treatment of Covid-19.

Cullinan Oncology completes $98.5m Series B financing

Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio.

Memo Therapeutics identifies potent SARS-CoV-2-neutralising antibodies from blood of recovered Covid-19 patients

Memo Therapeutics, an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a Covid-19 immunotherapy.

AstraZeneca partners with Accent to develop cancer therapeutics

AstraZeneca has joined forces with Accent Therapeutics for the development and commercialisation of advanced therapeutics targeting RNA-modifying proteins (RMPs) to treat cancer.

AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19

AgeX Therapeutics, a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes.